Shandong Wohua Pharmaceutical Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Yingzi Zeng

İcra Kurulu Başkanı

CN¥552.0k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	4.9yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	5.3yrs
Yönetim Kurulu ortalama görev süresi	4.8yrs

Son yönetim güncellemeleri

Recent updates

CEO

Yingzi Zeng (61 yo)

4.9yrs

Görev süresi

CN¥552,000

Tazminat

Ms. Yingzi Zeng is President of Shandong Wohua Pharmaceutical Co., Ltd. from December 05, 2019.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yingzi Zeng	President	4.9yrs	CN¥552.00k	Veri yok
Caixia Zhao	Board Secretary & Vice Chairman	5.8yrs	CN¥957.60k	0.0097% CN¥ 275.7k
Jiong Wang	CFO, VP & In Charge of Accounting	13.9yrs	CN¥723.20k	Veri yok
Qian Yang	Deputy General Manager	2.8yrs	CN¥1.71m	Veri yok

5.3yrs

Ortalama Görev Süresi

55.5yo

Ortalama Yaş

Deneyimli Yönetim: 002107 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Caixia Zhao	Board Secretary & Vice Chairman	5.8yrs	CN¥957.60k	0.0097% CN¥ 275.7k
Bing Xian Zhao	Chairman of the Board	18.6yrs	Veri yok	Veri yok
Ge Zhang	Director	15.4yrs	CN¥957.60k	1.74% CN¥ 49.8m
Shengting Li	Non-Independent Director	2.8yrs	CN¥684.00k	Veri yok
Wenjun Yin	Non-Employee Chairman of the Board of Supervisors	7.5yrs	Veri yok	Veri yok
Bofang Liu	Non-Employee Supervisor	5.8yrs	Veri yok	Veri yok
Lijuan Liu	Employee Representative Supervisor	5.8yrs	Veri yok	Veri yok
Wanhui Zhou	Supervisor	3.8yrs	Veri yok	0.0016% CN¥ 47.1k
Yong Chen	Non-Independent Director	2.8yrs	CN¥387.50k	Veri yok
Mingqin Gao	Independent Director	2.8yrs	CN¥120.00k	Veri yok
Junli Yu	Independent Director	2.8yrs	CN¥120.00k	Veri yok
Yuesheng Wang	Independent Director	1.6yrs	CN¥70.00k	Veri yok

4.8yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 002107 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).

Shandong Wohua Pharmaceutical Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Shandong Wohua Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

High number of new directors

High number of new directors

High number of new directors

High number of new directors

Shandong Wohua Pharmaceutical Co., Ltd. Announces Executive Appointments

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.019 (vs CN¥0.042 in 3Q 2023)

Shandong Wohua Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.002 (vs CN¥0.019 in 2Q 2023)

Now 21% undervalued after recent price drop

Shandong Wohua Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 03, 2024

Now 22% undervalued after recent price drop

First quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.04 in 1Q 2023)

Investor sentiment deteriorates as stock falls 18%

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.19 in FY 2022)

Shandong Wohua Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Now 22% overvalued

Now 23% overvalued

Investor sentiment improves as stock rises 19%

Investor sentiment deteriorates as stock falls 20%

Shandong Wohua Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.042 (vs CN¥0.04 in 3Q 2022)

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: CN¥0.019 (vs CN¥0.05 in 2Q 2022)

Shandong Wohua Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Jul 29, 2023

Full year 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.28 in FY 2021)

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.06 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.09 in 2Q 2021)

Now 21% undervalued after recent price drop

High number of new directors

First quarter 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.09 in 1Q 2021)

High number of new directors

High number of new directors

Shandong Wohua Pharmaceutical Co., Ltd. Announces Executive Appointments

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.081 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.075 in 1Q 2020)

New 90-day low: CN¥7.39

New 90-day low: CN¥7.55

Shandong Wohua Pharmaceutical Co., Ltd., Annual General Meeting, Feb 19, 2021

Full year 2020 earnings released: EPS CN¥0.31

Full year 2020 earnings released: EPS CN¥0.31

Investor sentiment improved over the past week

New 90-day low: CN¥8.10

New 90-day low: CN¥8.90

Third quarter earnings released

Shandong Wohua Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 16, 2020

New 90-day low: CN¥9.10

New 90-day low - CN¥10.07

Shandong Wohua Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Jul 16, 2020

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş